RTP Mobile Logo
RTP TV: Part I — Triple-Negative Breast Cancer: The New Biology
Released June 2011

This unique eight-part online, integrated educational course was designed to provide an array of perspectives relevant to the current and future treatment of several different solid tumors and hematologic cancers. Part I (originally held June 14, 2011) features Drs Joyce O'Shaughnessy and Eric P Winer discussing the management of triple-negative breast cancer. (Webinar)

CE Disclosures and Faculty Information


    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.


    Triple-negative breast cancer (TNBC) represents a more aggressive, higher-risk phenotype with an increased incidence of distant recurrence and death compared to other types of breast cancer. Despite an overall increase in knowledge of the biologic and natural history of TNBC, inadequate effective therapies for this patient subset persist. To offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists, hematology-oncology fellows and other healthcare providers must be well informed of these advances. This program uses a review of recent ASCO papers and other relevant publications, faculty case presentations, Q&A and discussion of community practice patterns to assist practicing clinicians with the incorporation of newly published data into best-practice breast cancer treatment algorithms.


    • Recognize the interrelationship between BRCA-deficient and triple-negative breast tumors.
    • Apply the results of current clinical research — including data sets presented at ASCO 2011 — to the evidence-based care of patients with TNBC.
    • Compare and contrast pivotal findings with PARP inhibitors in the first-line or subsequent treatment of metastatic TNBC.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component. The participant should watch the video.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Joyce O’Shaughnessy, MD
    Co-Director, Breast Cancer Research Program
    Baylor-Charles A Sammons Cancer Center
    Texas Oncology, PA
    US Oncology
    Dallas, Texas

    Advisory Committee: Biogen Idec, Bristol-Myers Squibb Company, Caris Diagnostics Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, GTx Inc, Johnson & Johnson Pharmaceuticals, Roche Laboratories Inc, Sanofi; Speakers Bureau: Bristol-Myers Squibb Company, Celgene Corporation, Sanofi.

    Eric P Winer, MD
    Thompson Investigator in Breast Cancer Research
    Chief, Division of Women's Cancers
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    No real or apparent conflicts of interest to disclose.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium — The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This program is supported by an educational grant from Sanofi.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: June 2011
    Expiration date: June 2012

Acknowledge and close

Watch Video
(WiFi is recommended for best performance):